CV Therapeutics’ Ranexa Grows In Fourth Quarter; Partner Talks Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
New heart indication, diabetes could be next, as pendulum swings to company’s favor, analyst tells “The Pink Sheet” DAILY.
You may also be interested in...
CVT gets $175M For Half Of Lexiscan Royalties
Cash adds flexibility to Ranexa partner talks, company tells “The Pink Sheet” DAILY.
CVT gets $175M For Half Of Lexiscan Royalties
Cash adds flexibility to Ranexa partner talks, company tells “The Pink Sheet” DAILY.
CV Therapeutics Seeks Ranexa Labeling Changes Based on MERLIN Study
sNDA includes new analysis of MERLIN-TIMI 36 data, which should eliminate safety concerns around QTc prolongation, clinical researchers report at the European Society of Cardiology.